Jiangsu Hengrui Pharmaceuticals (600276.SH): Clinical research on the combined use of SHR-1826 with other drugs for injection has been approved.
Jiangsu Hengrui Medicine Co., Ltd. (600276.SH) announced that its subsidiaries, Suzhou Shengdiya Biopharmaceutical Co., Ltd. and Shanghai Shengdi...
Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that its subsidiary Suzhou Shengdiya Biopharmaceutical Co., Ltd. and Shanghai Shengdi Pharmaceuticals Co., Ltd. have received approval from the National Medical Products Administration for the clinical trial of injection SHR-1826, Adebril monoclonal antibody injection, and Bevacizumab monoclonal antibody injection. The companies will soon begin a multicenter, open-label phase Ib/II clinical study to evaluate the safety, tolerability, and effectiveness of injection SHR-1826 in combination with other anti-tumor treatments in patients with solid tumors.
Related Articles
Novo Nordisk A/S Sponsored ADR Class B (NVO.US) plans to apply for US regulatory approval for the high-dose Wegovy.
CHINA JINMAO (00817) plans to increase its capital to Beijing Chao by 350 million yuan and to Beijing Manmao by 2.15 billion yuan.
Selected A-share Announcement | Brother Enterprises Holding(002562.SZ) expects a year-on-year increase in performance of 207%-253% for the first three quarters.
Novo Nordisk A/S Sponsored ADR Class B (NVO.US) plans to apply for US regulatory approval for the high-dose Wegovy.
CHINA JINMAO (00817) plans to increase its capital to Beijing Chao by 350 million yuan and to Beijing Manmao by 2.15 billion yuan.
Selected A-share Announcement | Brother Enterprises Holding(002562.SZ) expects a year-on-year increase in performance of 207%-253% for the first three quarters.
